Life Science Nord takes stock of a positive BIO-Europe in Hamburg

The North German cluster management Life Science Nord is more than happy with the results of the international Biotech pharmaceuticals conference that took place from 11 to 13 November at the Hamburg Messe. At the closing reception on Wednesday afternoon, LSN cluster manager Dr Hinrich Habeck passed the baton for the role of regional host of BIO-Europe 2020 to the Munich cluster BIO M, marking the end of this year’s conference which is regarded as the most important of its kind in Europe. “Our first indications are very positive” Habeck summarises. “We’ve used the three-day event to put the North German life sciences scene into the spotlight.” From over 20 companies represented on the North German group stand, it was above all the four industry partners from the regional host committee who made the industry region and its skills visible for visitors. “We would like to thank once again Nordmark, Eppendorf, Indivumed and Evotec for their dedication to the North German location.”

Anniversary may have broken records

 

BIO-Europe boasted around 4,400 participants from over 60 countries. According to the event organiser EBD , the 2018 record was broken this year with almost 28,000 one-to-one meetings. One-to-one meetings are short half-hour discussions to initiate new partnerships and business relationships and are arranged in advance via an online platform. They offer the advantage of being an effective way to make contact. As well as personal meetings, the congress visitors were able to find out about current issues such as immune oncology, digital medicine, women’s health and cardiology in a varied programme with renowned experts. Furthermore there were panels on business topics such as investment, sponsoring and market access. One highlight on Tuesday was a StartUp-Slam in which two companies from the Life Science Nord cluster, Osteolabs and Axiom insights also took part. All North German participants reported that they made many interesting and promising new contacts that will promote their business development.

More Information

More News

Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19.
Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19. (Photo Credit: Alissa Eckert, MSMI; Dan Higgins, MAMS)

tiakis: Treatment of COVID-19

tiakis Biotech AG announced today that a first patient has been dosed in the COMCOVID trial, a Phase Ib/II trial evaluating the Company’s key investigational ...

Read more …
The paper's main author Vasundara Srinivasan at an X-ray set-up to test protein crystals in the lab. Credit: University of Hamburg, Susanna Gevorgyan (Credit: © University of Hamburg, Susanna Gevorgyan)

Natural substances show promise against coronavirus

Three natural compounds present in foods like green tea, olive oil and red wine are promising candidates for the development of drugs against the coronavirus. ...

Read more …
The molecule has shown great potential to produce a powerful antiviral response against infections with SARS-CoV-2. (Picture: ©NicoElNino/adobe.stock.com)

Evotec: € 7.5 m grant for development of COVID-19 therapeutic

Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the ...

Read more …